CoChat

Future Artificial Pancreas Technology for Type 1 Diabetes: What Do Users Want?

Barnard, Katharine D., Pinsker, Jordan E., Oliver, Nick, Astle, Annabel, Dassau, Eyal, Kerr, David · 2015 · Diabetes Technology & Therapeutics
Cited by 52

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The primary focus of artificial pancreas (AP) research has been on technical achievements, such as time in range for glucose levels or prevention of hypoglycemia. Few studies have attempted to ascertain the expectations of users of AP technology. SUBJECTS AND METHODS: Persons with type 1 diabetes and parents of children with type 1 diabetes were invited to take part in an online survey concerning future use and expectations of AP technology. The survey was advertised via Twitter, Facebook, and DiabetesMine, plus advocacy groups and charities including INPUT, Diabetes UK, and the Diabetes Research and Wellness Foundation. Quantitative responses were categorized on a 5-point Likert scale. Free text responses were analyzed using content analysis. RESULTS: Two hundred sixty-six surveys were completed over a 1-month period. Two hundred forty participants indicated they were highly likely to use a fully automated 24-h AP. Approximately half of the respondents indicated they would be likely to use a device that only functioned overnight. Size, visibility, and lack of effectiveness were the top reasons for not wanting an AP. Despite perceived potential downsides, participants expressed a strong need for a device that will help minimize the burden of disease, help facilitate improved psychosocial functioning, and improve quality of life. CONCLUSIONS: The views of people who would use an AP are crucial in the development of such devices to ensure they are fit for use alongside biomedical and engineering excellence. Without this, it is unlikely that an AP will be sufficiently successful to meet the needs of users and to achieve their ultimate goals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2014.0316

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 52

Metadata

Authors
Barnard, K. D., Pinsker, J. E., Oliver, N., Astle, A., Dassau, E., & Kerr, D.
Venue
Diabetes Technology & Therapeutics
Published
2015-05
Volume
17
Issue
5
Pages
311-315
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W2323786862
Cited by
52
References
2
FWCI
6.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Future Artificial Pancreas Technology for Type 1 Diabetes: What Do Users Want? https://app.cochat.ai/papers/10.1089/dia.2014.0316
The paper
Barnard, K. D., Pinsker, J. E., Oliver, N., Astle, A., Dassau, E., & Kerr, D. (2015). Future Artificial Pancreas Technology for Type 1 Diabetes: What Do Users Want? Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2014.0316

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.